Robert J. Hugin
Chief executive: Celgene (before 2014 to 1 Mar 2016)
7commitments announced
2with a clear outcome
0met on time
–rate shown after 15 outcomes
Commitments are credited to the chief executive in office on the day they were announced. Where a deadline fell after the leader left, the entry is marked. Sources for each leadership change: Celgene filing.
Commitments announced under Robert J. Hugin
| Celgeneannounced 28 Jan 2016 | Begin additional clinical trials in NDMM and DLBCL due after leader left | No record found31 Mar 2016 |
| Celgeneannounced 28 Jan 2016 | Report data from the PSA-006 trial due after leader left | No record found31 Dec 2016 |
| Celgeneannounced 28 Jan 2016 | Submit ABRAXANE for early-stage breast cancer for regulatory approval in Europe due after leader left | Not met31 Dec 2016 |
| Celgeneannounced 28 Jan 2016 | Report data from the phase III ETNA trial due after leader left | No record found31 Dec 2016 |
| Celgeneannounced 28 Jan 2016 | Report data from the registration-enabling endoscopic trial with GED-0301 due after leader left | Withdrawn31 Dec 2017 |
| Celgeneannounced 28 Jan 2016 | Report data from the RELEVANCE trial due after leader left | No record found31 Dec 2017 |
| Celgeneannounced 28 Jan 2016 | Report data from the OPTIMISMM trial due after leader left | No record found31 Dec 2018 |
Is this record wrong, or are you Robert J. Hugin? Add a statement or ask for a correction.